![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Towards elimination: A clinical and public health approach to control of hepatitis C and B infection in England
|
|
|
EASL 2022 June 22-26 London
Prof. Graham R Foster
Prof Hepatology QMUL/Barts Health
NHSE Clinical Lead for HCV
![0706221](../images/070622/070622-17/0706221.gif)
![0706222](../images/070622/070622-17/0706222.gif)
![0706223](../images/070622/070622-17/0706223.gif)
![0706224](../images/070622/070622-17/0706224.gif)
![0706225](../images/070622/070622-17/0706225.gif)
every network has a target & we monitor them on week by week basis.
![0706226](../images/070622/070622-17/0706226.gif)
![0706227](../images/070622/070622-17/0706227.gif)
![0706228](../images/070622/070622-17/0706228.gif)
programs we have initiated.
![0706229](../images/070622/070622-17/0706229.gif)
![07062210](../images/070622/070622-17/07062210.gif)
![07062211](../images/070622/070622-17/07062211.gif)
tough to implement..
![07062212](../images/070622/070622-17/07062212.gif)
increase in liver cancers in part due to not doing surveillance post cure. all too often patients fall out of the scanning process - with the marginalised groups we are treating follow up attendance is poor. We are trying to address this with a program of out-reach scanning involving community vans with peers, hopefully that will improve things but, I suspect, we are going to see a rise in HCC
![07062213](../images/070622/070622-17/07062213.gif)
![07062214](../images/070622/070622-17/07062214.gif)
![07062215](../images/070622/070622-17/07062215.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|